Document Detail

Use of an in vitro absorption model system for predicting sustained release of verapamil.
MedLine Citation:
PMID:  1445475     Owner:  NLM     Status:  MEDLINE    
It is shown that it is possible to characterize sustained release formulations in vitro using not only dissolution data but also an absorption model system. The mean dissolution time (MDT) has been shown to be a suitable parameter for evaluating sustained release formulations in vitro. t1/2 and mean residence time (MRT) have been shown to be convenient pharmacokinetic parameters for characterizing sustained release formulations. For comparing in vitro and in vivo results the quotients MDT normal/MDT retard and MRT normal/MRT retard do seem to be useful.
R Neubert; F Fahr; C Mäder; L Lücke; G Fries; G Rostock
Related Documents :
15180335 - Comparison of the use of liver models for predicting drug clearance using in vitro kine...
18342485 - A mathematical model of the in vitro keratinocyte response to chromium and nickel expos...
9746095 - An auricular paper model.
22108565 - Performance evaluation of two commercial chemiluminescence no(x) analysers according to...
19682365 - An xml transfer schema for exchange of genomic and genetic mapping data: implementation...
23441685 - Arabic validation of the internet addiction test.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Arzneimittel-Forschung     Volume:  42     ISSN:  0004-4172     ISO Abbreviation:  Arzneimittelforschung     Publication Date:  1992 Sep 
Date Detail:
Created Date:  1992-12-17     Completed Date:  1992-12-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0372660     Medline TA:  Arzneimittelforschung     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  1098-100     Citation Subset:  IM    
Department of Pharmacy, Martin-Luther-University, Halle/Saale, Fed. Rep. of Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Delayed-Action Preparations
Intestinal Absorption
Middle Aged
Models, Biological
Verapamil / administration & dosage,  pharmacokinetics*
Reg. No./Substance:
0/Delayed-Action Preparations; 52-53-9/Verapamil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pretreatment anxiety level as differential predictor in outpatients with panic disorder.
Next Document:  Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive he...